StockNews.AISignal intelligence
Company intelligence

INO

Inovio Pharmaceuticals, Inc. · NASDAQ · Healthcare

Price$1.43-2.05% · −$0.03
Market cap98.8MEquity value
P / E-1.2Trailing ratio
Volume5.15MLatest session
Market data

INO price chart

TradingView
Related signals
1 min delayed

Browse public INO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

INOOct 30, 2026+213.75% since signal

INOVIO's VOCERYQ FDA accelerated approval could transform RRP treatment landscape

FDA grants accelerated approval for VOCERYQ to reduce surgeries in adults with RRP, supported by RRP-001 data showing a 27% complete response after 12 months. VOCERYQ will be available to order and ship in about 60 days, with full commercial launch targeted for Q1 2027. This milestone validates INOVIO's DNA medicines platform and could alter the standard of care for RRP patients, driving early revenue with conservative confirmatory trial expectations.

View signal analysis
Research

Company intelligence